Nullane salus extra ecclesiam
Randomized clinical trials are not relevant for infectious disease outbreaks due to a new pathogen, for which public health decisions have to be made urgently. An approach based on group comparisons, in silico, may provide valuable results in a reasonably short period of time for a negligible amount...
Main Authors: | P. Gautret, D. Raoult |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2020-09-01
|
Series: | New Microbes and New Infections |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2052297520300664 |
Similar Items
-
EXTRA ECCLESIAM NULLA SALUS
by: João Batista Libânio
Published: (1973-01-01) -
Zinc(II)—The Overlooked Éminence Grise of Chloroquine’s Fight against COVID-19?
by: Aleksandra Hecel, et al.
Published: (2020-09-01) -
SARS-CoV-2 and the Use of Chloroquine as an Antiviral Treatment
by: Mathieu E. Rebeaud, et al.
Published: (2020-04-01) -
Antiviral Activity of Repurposing Ivermectin against a Panel of 30 Clinical SARS-CoV-2 Strains Belonging to 14 Variants
by: Océane Delandre, et al.
Published: (2022-04-01) -
Effect of Hydroxychloroquine on QTc in Patients Diagnosed with COVID-19: A Systematic Review and Meta-Analysis
by: Angelos Arfaras-Melainis, et al.
Published: (2021-05-01)